Cargando…

In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy

OBJECTIVE: Baricitinib seems a promising therapy for COVID-19. To fully-investigate its effects, we in-vitro evaluated the impact of baricitinib on the SARS-CoV-2-specific-response using the whole-blood platform. METHODS: We evaluated baricitinib effect on the IFN-γ-release and on a panel of soluble...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrone, Linda, Petruccioli, Elisa, Alonzi, Tonino, Vanini, Valentina, Cuzzi, Gilda, Najafi Fard, Saeid, Castilletti, Concetta, Palmieri, Fabrizio, Gualano, Gina, Vittozzi, Pietro, Nicastri, Emanuele, Lepore, Luciana, Grifoni, Alba, Antinori, Andrea, Vergori, Alessandra, Ippolito, Giuseppe, Cantini, Fabrizio, Goletti, Delia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904476/ https://www.ncbi.nlm.nih.gov/pubmed/33639176 http://dx.doi.org/10.1016/j.jinf.2021.02.023

Ejemplares similares

A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients
por: Petrone, Linda, et al.
Publicado: (2021)

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2
por: Petrone, Linda, et al.
Publicado: (2021)

Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection
por: Petruccioli, Elisa, et al.
Publicado: (2021)

Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy
por: Najafi-Fard, Saeid, et al.
Publicado: (2022)

In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses
por: Najafi Fard, Saeid, et al.
Publicado: (2021)

Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients
por: Aiello, Alessandra, et al.
Publicado: (2021)

VIDAS(®) TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB
por: Petruccioli, E., et al.
Publicado: (2022)

Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease
por: Petruccioli, Elisa, et al.
Publicado: (2021)

Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection
por: Najafi-Fard, Saeid, et al.
Publicado: (2023)

Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
por: Petrone, Linda, et al.
Publicado: (2022)

Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases
por: Petrone, Linda, et al.
Publicado: (2022)

Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection
por: Petruccioli, Elisa, et al.
Publicado: (2018)

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled
por: Goletti, Delia, et al.
Publicado: (2021)

Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry
por: Alonzi, Tonino, et al.
Publicado: (2019)

Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
por: Aiello, Alessandra, et al.
Publicado: (2022)

Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy
por: Alonzi, Tonino, et al.
Publicado: (2021)

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4(+) and CD8(+) T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
por: Aiello, Alessandra, et al.
Publicado: (2022)

Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy
por: Musso, Maria, et al.
Publicado: (2021)

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
por: Cantini, Fabrizio, et al.
Publicado: (2017)

Higher Frequency of T-Cell Response to M. tuberculosis Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood
por: Chiacchio, Teresa, et al.
Publicado: (2011)

PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease
por: Grassi, Germana, et al.
Publicado: (2021)

Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection
por: Chiacchio, Teresa, et al.
Publicado: (2017)

Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis
por: Grifoni, Alba, et al.
Publicado: (2023)

ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2021)

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
por: D’Abramo, Alessandra, et al.
Publicado: (2021)

Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages
por: La Manna, Marco Pio, et al.
Publicado: (2017)

National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management
por: Nicastri, Emanuele, et al.
Publicado: (2020)

Zika Virus Infection in the Central Nervous System and Female Genital Tract
por: Nicastri, Emanuele, et al.
Publicado: (2016)

Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants
por: Alonzi, Tonino, et al.
Publicado: (2022)

Polyfunctional Specific Response to Echinococcus Granulosus Associates to the Biological Activity of the Cysts
por: Petrone, Linda, et al.
Publicado: (2015)

Usefulness of bronchoalveolar lavage in the management of patients presenting with lung infiltrates and suspect COVID-19-associated pneumonia: A case report
por: Gualano, Gina, et al.
Publicado: (2020)

Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
por: Farroni, Chiara, et al.
Publicado: (2022)

Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis
por: Farroni, Chiara, et al.
Publicado: (2022)

Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation
por: Ciccosanti, Fabiola, et al.
Publicado: (2022)

Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016
por: Nicastri, Emanuele, et al.
Publicado: (2016)

IP-10 detection in urine is associated with lung diseases
por: Cannas, Angela, et al.
Publicado: (2010)

Multicenter analysis of sputum microbiota in tuberculosis patients
por: Sala, Claudia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qvft99euku7ben2ttncjcmdfg1